Clinical trials: Sexually Transmitted Infection (STI)
Human Papilloma Virus Infection
Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)
This study is a cross-sectional study to evaluate accuracy of high-risk DNA-HPV testing using HPV Diagnostic Kit (Bio Farma) compared to Standard Kit (COBAS® 6800 HPV from Roche Molecular Systems) RT-PCR based in urine and…
- Trial name
- NCT06111911
- Testing
- HPV Diagnostic Kit (Bio Farma)
- Where
- Indonesia
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
AIDS
A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment
The primary objective of this trial was to evaluate the safety and preliminary evaluation of Azvudine tablets (FNC) in combination with reverse transcriptase inhibitors therapy in treatment-naive patients with HIV infection.; the…
- Trial name
- FNC (NCT04109183)
- Testing
- The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Toxoplasmosis, Cerebral, HIV Infections
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
To evaluate the safety and tolerance of atovaquone (566C80) in AIDS patients with central nervous system (CNS) toxoplasmosis. To evaluate the efficacy of 566C80 in the acute treatment and suppression of CNS toxoplasmosis in AIDS…
- Trial name
- NCT00001994
- Testing
- Atovaquone
- Where
- 22 sites in United States, Canada
- Sponsor
- Glaxo Wellcome
Infections, Papillomavirus
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or…
- Trial name
- NCT01462357
- Testing
- Cervarix, Gardasil
- Where
- 21 sites in France, Hong Kong and 2 more
- Volunteers
- 1,079 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
A single tablet regimen (STR) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF) is the first complete HAART that is offered as one tablet once a day.
- Trial name
- ONCE (NCT00615745)
- Testing
- Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
- Where
- United Kingdom
- Volunteers
- 115 people
- Sponsor
- Gilead Sciences
HIV Infections
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
Human immunodeficiency virus (HIV)-1 infected participants receiving long-term therapy with lamivudine or emtricitabine (nucleoside reverse transcriptase inhibitors [NRTIs]) are at risk for the development of a mutation at…
- Trial name
- Resistance (NCT00312039)
- Testing
- Elvucitabine, Lamivudine
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Infection, Human Immunodeficiency Virus
Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529
The current food effect study is being performed to support a Phase 3 study with BMS 663068. Results from this study will inform whether patients in the upcoming Phase 3 study can be given the flexibility to dose BMS-663068 in…
- Trial name
- NCT02164045
- Testing
- BMS-663068
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infections, Papillomavirus
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years
The purpose of this study is to evaluate the immunogenicity and safety of two doses of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine when co-administered with GSK Biologicals' HAV vaccine according to 0, 6 month schedule…
- Trial name
- NCT02082639
- Testing
- Cervarix™, Havrix
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus (HIV)
An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate
The purpose of this study is to describe the effectiveness of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), measured as virological response at Week 48 as per Food and Drug Administration (FDA) snapshot…
- Trial name
- DIAMANTE (NCT03577470)
- Testing
- D/C/F/TAF Fixed-Dose Combination (FDC)
- Where
- 18 sites in Italy
- Volunteers
- 246 people
- Sponsor
- Janssen-Cilag S.p.A.
Infection, Human Immunodeficiency Virus
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir (DTG) containing regimen in HIV-1 infected, antiretroviral therapy (ART)-experienced adults with current or historical failure on an…
- Trial name
- VIKING-3 (NCT01328041)
- Testing
- dolutegravir
- Where
- 89 sites in United States, Belgium and 5 more
- Volunteers
- 183 people
- Sponsor
- ViiV Healthcare
HIV Infections
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
- Trial name
- NCT00059462
- Testing
- Interleukin-2 SA, HAART
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Herpes Genitalis
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection
This is a randomized, double-blind, double-dummy study of single dose HDIT101 versus Standard of Care Valaciclovir. HSV-2-positive patients with at least 4 anogenital herpes lesions in the last 12 months (or at least 2 herpes…
- Trial name
- MATCH-2 (NCT04165122)
- Testing
- HDIT101, Valaciclovir
- Where
- 8 sites in Germany
- Volunteers
- 122 people
- Sponsor
- Heidelberg ImmunoTherapeutics GmbH
HIV Infections
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.
- Trial name
- NCT00002266
- Testing
- AS-101
- Where
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Papillomavirus Infections
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
This study will evaluate the safety, tolerability, and immunogenicity of V503 in Japanese girls between the ages of 9 and 15 and will determine whether V503 induces an acceptable immune response to all human papillomavirus (HPV)…
- Trial name
- NCT01254643
- Testing
- V503
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection, Infection, Human Immunodeficiency Virus
Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.
To evaluate the single dose relative bioavailability of GSK1265744 10mg administered in either oral solution fasted, two 5mg tablets fasted, or two 5mg tablets following a moderate meal.
- Trial name
- NCT00812318
- Testing
- GSK1265744 10 mg oral solution, GSK1265744 5 mg tablet
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: If taking MK-8527 once a month works to prevent HIV-1 infection better than a…
- Trial name
- NCT07071623
- Testing
- MK-8527, Emtricitabine/tenofovir disoproxil (FTC/TDF)
- Where
- 30 sites in Kenya, South Africa and 1 more
- Volunteers
- 4,580 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously
This is an open label study (no placebos are used; all patients will receive the true medication) to evaluate the effectiveness of TMC114/rtv in treatment naÃ-ve (never previously received anti-HIV drugs), HIV 1 infected patients.
- Trial name
- NCT00513513
- Testing
- TMC114 (darunavir) / ritonavir
- Volunteers
- 7 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children
To determine the pharmacokinetic properties, tolerance and safety of 2 formulations of saquinavir, given in combination with 2 nucleoside antiretroviral drugs (part 1) or in combination with nelfinavir and nucleoside…
- Trial name
- NCT00002380
- Testing
- Nelfinavir mesylate, Saquinavir
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
This is an international study of vicriviroc in 500 adult HIV-infected subjects who are failing standard antiretroviral therapy (ART). HIV must be of a certain type known as R5/X4-mixed tropic.
- Trial name
- NCT00243568
- Testing
- Vicriviroc
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Healthy
Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.
To investigate the safety and pharmacokinetic of BI 224436 in healthy male volunteers following oral administration of repeated doses for 10 days within 8 dosing regimens.
- Trial name
- NCT01276990
- Testing
- BI 224436
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.